Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Urolithin A is a gut-derived metabolite formed from ellagitannins found in foods such as pomegranates, walnuts, and some berries. In recent years, preclinical and early clinical research has suggested that Urolithin A may have potential as an adjunct in cancer therapy, particularly for mitigating some side effects associated with cancer treatments. The primary mechanisms involve its antioxidant and anti-inflammatory properties, as well as its ability to induce mitophagy (the selective degradation of damaged mitochondria), which may help reduce cellular stress and improve cellular health during chemotherapy or radiation therapy.

Several animal and in vitro studies have demonstrated that Urolithin A can decrease markers of oxidative stress and inflammation, both of which are elevated in cancer patients undergoing treatment. These effects could, in theory, help reduce fatigue, muscle wasting, and other side effects of cancer therapy. Furthermore, there is some evidence that Urolithin A may enhance the effectiveness of certain chemotherapeutic agents or reduce their toxicity to normal cells by modulating cellular pathways involved in apoptosis and cell survival.

However, robust clinical trials in humans specifically addressing the use of Urolithin A for reducing side effects in cancer treatment are still limited. Most evidence comes from preclinical models, and data in cancer patients is preliminary. As such, while the underlying science is promising, more high-quality clinical studies are needed to confidently recommend Urolithin A in this context.

More about Urolithin A
More about Cancer Treatment (reducing side effects)

Other ingredients used for Cancer Treatment (reducing side effects)

Other health conditions supported by Urolithin A

Products containing Urolithin A

Pure Encapsulations Renual